PharVision Advisers LLC Takes $301,000 Position in GeneDx Holdings Corp. (NASDAQ:WGS)

PharVision Advisers LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,910 shares of the company's stock, valued at approximately $301,000.

A number of other large investors have also recently bought and sold shares of WGS. MCF Advisors LLC grew its holdings in shares of GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after acquiring an additional 182 shares in the last quarter. Sterling Capital Management LLC boosted its position in GeneDx by 877.8% during the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock valued at $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC bought a new position in GeneDx in the fourth quarter valued at approximately $28,000. Lazard Asset Management LLC bought a new position in GeneDx in the fourth quarter valued at approximately $35,000. Finally, Comerica Bank acquired a new position in shares of GeneDx during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Performance

Shares of NASDAQ:WGS traded up $0.43 on Tuesday, hitting $72.03. The company had a trading volume of 254,127 shares, compared to its average volume of 766,545. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -36.73 and a beta of 1.96. The stock has a 50 day moving average price of $84.28 and a 200 day moving average price of $82.37. GeneDx Holdings Corp. has a 1-year low of $19.54 and a 1-year high of $117.75. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.11 by $0.17. The business had revenue of $87.12 million during the quarter, compared to the consensus estimate of $79.90 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on WGS shares. Wells Fargo & Company cut their price objective on GeneDx from $105.00 to $78.00 and set an "equal weight" rating for the company in a report on Thursday, May 1st. The Goldman Sachs Group upped their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Friday, May 9th. Guggenheim assumed coverage on shares of GeneDx in a research note on Thursday, May 15th. They set a "buy" rating and a $88.00 price objective on the stock. Finally, TD Securities dropped their target price on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, GeneDx presently has an average rating of "Moderate Buy" and an average target price of $86.75.

Insider Activity

In other news, CFO Kevin Feeley sold 388 shares of the business's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total value of $43,878.92. Following the completion of the sale, the chief financial officer now owns 3,337 shares of the company's stock, valued at approximately $377,381.33. The trade was a 10.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Katherine Stueland sold 2,731 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.73, for a total transaction of $258,707.63. Following the transaction, the chief executive officer now directly owns 7,752 shares in the company, valued at approximately $734,346.96. This represents a 26.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,390 shares of company stock valued at $13,043,288. 29.60% of the stock is owned by insiders.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.